Support for KISQALI prescribers
These resources are designed to help KISQALI prescribers. You can preview and download these resources, and if you would like to receive more information or copies of any materials, please contact a Novartis representative.
YOUR CHOICE WITH KISQALI
A comprehensive dispensing, delivery and monitoring support programme for you and your patients.
Therapy management guide GB
This guide provides information for Great Britain healthcare professionals about how to use KISQALI, detailing posology, monitoring and managing adverse events.
Therapy management guide NI
This guide provides information for Northern Ireland healthcare professionals about how to use KISQALI, detailing posology, monitoring and managing adverse events.
PATIENT INFORMATION BOOKLET: KISQALI + AROMATASE INHIBITOR
This booklet provides information for patients about what to expect from treatment with KISQALI + AI.
PATIENT INFORMATION BOOKLET: KISQALI + FULVESTRANT
This booklet provides information for patients about what to expect from treatment with KISQALI + fulvestrant.
KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.*1
*KISQALI is not recommended to be used in combination with tamoxifen1
AI, aromatase inhibitor.
- KISQALI (ribociclib). Summary of Product Characteristics.